Cullinan Therapeutics, Inc.
CGEM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CGEM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CGEM
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies, with a pipeline including CLN-049 and velinotamig, and reported $78.6M in cash as of June 30, 2026.
Key risk: No approved products
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.40B
Cash Runway
25.4 moLead Asset
CLN-049 (Phase 1/Phase 2)
Next Catalyst
Phase1_Start · Oct 15, 2026Financial data as of Jun 30, 2026.
Tracking 8 pipeline candidates · 8 clinical trials · 2 catalysts for Cullinan Therapeutics, Inc..
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies, with a pipeline including CLN-049 and velinotamig, and reported $78.6M in cash as of June 30, 2026.
- Cash and equivalents of $78.6M as of 2026-06-30 [sec].
- Shareholders' equity of $408.7M as of 2026-06-30 [sec].
- Pipeline includes CLN-049 (Phase 1b dose escalation/expansion study in combination with azacitidine) and velinotamig (Phase 1b/2a study for relapsing/refractory adults) [sec_mda · as of 2026-08-06].
- Company expects expenses to increase due to ongoing R&D, preclinical studies, and clinical trials [sec_mda · as of 2026-08-06].
- Future funding requirements are uncertain and depend on factors such as trial results, regulatory challenges, and potential acquisitions [sec_mda · as of 2026-08-06].
What works
- Cash position of $78.6M as of 2026-06-30 provides near-term operational runway [sec].
- Shareholders' equity of $408.7M as of 2026-06-30 indicates a solid balance sheet [sec].
- Pipeline includes two clinical-stage candidates (CLN-049 and velinotamig) with upcoming trial initiations [sec_mda · as of 2026-08-06].
What to weigh
- Company has no approved products and is entirely pre-revenue, with expenses expected to increase [sec_mda · as of 2026-08-06].
- Future funding requirements are uncertain and may depend on successful trial outcomes and capital markets [sec_mda · as of 2026-08-06].
- Clinical development risks include potential delays, failed studies, safety issues, or regulatory challenges [sec_mda · as of 2026-08-06].
From the filings
Quoted directly from source documents.
Expenses expected to increase due to ongoing activities
“We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we: • continue research and development of our current and future product candidates and programs; • conduct preclinical studies and clinical trials for our current and future product candidates;”
SEC MD&A · August 6, 2026
Uncertainty of future funding requirements
“Because of the numerous risks and uncertainties associated with research, development and commercialization of our product candidates and programs, we are unable to estimate the exact amount of our working capital requirements.”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-10-15 · Phase 1 Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and V — Initiation of a Phase 1b study for CLN-049 in combination with azacitidine; watch for enrollment updates and initial safety data.
- 2026-12-01 · Phase 2 Start: A Phase 1b/2a, Open-label Study of Velinotamig for the Treatment of Adults With Relapsing and Refrac — Initiation of a Phase 1b/2a study for velinotamig; watch for patient recruitment and early efficacy signals.
Risks & what to watch (4)›
Key risks
- No approved products — Company has no marketed products and is entirely dependent on clinical-stage pipeline [sec_mda · as of 2026-08-06].
- Increasing expenses — Expenses expected to rise with R&D and clinical trials, potentially straining cash runway [sec_mda · as of 2026-08-06].
- Clinical trial risks — Delays, failures, safety issues, or regulatory challenges could materially impact pipeline [sec_mda · as of 2026-08-06].
- Funding uncertainty — Unable to estimate exact working capital needs; may require additional financing [sec_mda · as of 2026-08-06].
What to watch
- Initiation of Phase 1b dose escalation/expansion study for CLN-049 in combination with azacitidine, expected October 2026 [catalyst_timeline].
- Initiation of Phase 1b/2a study for velinotamig in relapsing/refractory adults, expected December 2026 [catalyst_timeline].
- Cash burn rate and any updates on financial runway in future SEC filings [sec_mda · as of 2026-08-06].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Cullinan Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cullinan Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
25.4 months
OCF -$38M
Lead: Phase 3
8 candidates
2 upcoming, next in ~46d
0 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
171
Total value held
$867.3M
| Holder | Shares | Value |
|---|---|---|
| lynx1 capital management lp | 8,963,500 | $127.4M |
| mpm bioimpact llc | 7,648,268 | $108.7M |
| bvf inc/il | 5,750,683 | $81.7M |
| vanguard capital management llc | 4,966,068 | $70.6M |
| blackrock, inc. | 4,449,966 | $63.2M |
| state street corp | 2,544,115 | $36.2M |
| rtw investments, lp | 1,705,960 | $24.2M |
| venrock adviser, llc | 1,379,965 | $19.6M |
| geode capital management, llc | 1,368,268 | $19.4M |
| siren, l.l.c. | 1,193,410 | $17.0M |
Showing top 10 of 171 institutional holders of Cullinan Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 20.3%
- Days to cover
- 12.5
- Shares short
- 8,799,071
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CGEM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cullinan Therapeutics, Inc.?
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oncology therapies, with a pipeline including CLN-049 and velinotamig, and reported $78.6M in cash as of June 30, 2026.
What is Cullinan Therapeutics, Inc.'s lead drug candidate?
Cullinan Therapeutics, Inc.'s most advanced tracked candidate is CLN-049 (Phase 1/Phase 2) for AML (Acute Myeloid Leukemia).
What is Cullinan Therapeutics, Inc.'s next catalyst?
Cullinan Therapeutics, Inc.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and V" — expected October 15, 2026.
Who is the CEO of Cullinan Therapeutics, Inc.?
Mr. Nadim Ahmed M.S. is the chief executive officer of Cullinan Therapeutics, Inc. (CGEM).
Where is Cullinan Therapeutics, Inc. headquartered?
Cullinan Therapeutics, Inc. (CGEM) is headquartered in Cambridge, MA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.